Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-092720
Filing Date
2024-08-07
Accepted
2024-08-07 16:01:32
Documents
86
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q srpt-20240630.htm   iXBRL 10-Q 3421794
2 EX-31.1 srpt-ex31_1.htm EX-31.1 11739
3 EX-31.2 srpt-ex31_2.htm EX-31.2 11790
4 EX-32.1 srpt-ex32_1.htm EX-32.1 8027
5 EX-32.2 srpt-ex32_2.htm EX-32.2 7956
  Complete submission text file 0000950170-24-092720.txt   11942784

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT srpt-20240630.xsd EX-101.SCH 1409422
88 EXTRACTED XBRL INSTANCE DOCUMENT srpt-20240630_htm.xml XML 2286325
Mailing Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142
Business Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142 617-274-4000
Sarepta Therapeutics, Inc. (Filer) CIK: 0000873303 (see all company filings)

EIN.: 930797222 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-14895 | Film No.: 241183456
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)